Sandoz filed a draft anti-dumping complaint with the European Commission on Thursday targeting imports of amoxicillin, a penicillin-family antibiotic active ingredient originating in China. The Swiss generics producer said it has the only sizeable vertically integrated penicillin production network remaining in Europe.
In its complaint, Sandoz identified several practices it says are distorting the market: sustained pricing below production cost, state subsidies to Chinese producers and a broad concentration of global production capacity in China. The company framed these dynamics as endangering independent antibiotic manufacturing capacity within Europe.
Chief Executive Richard Saynor cautioned about the broader implications for supply resilience and strategic trade policy. He highlighted that up to 90% of global antibiotic active ingredients are now produced outside Europe and argued that measures are required to preserve a domestic manufacturing base for antibiotics.
"Safeguarding antibiotic supply is not only a health policy issue, but a question of economic security and strategic trade policy. Europe must act now to safeguard independent supply in years to come," Saynor said.
The complaint cites specific market distortions it attributes to Chinese production and policy, but the company did not provide additional figures beyond its assertion about the share of global production located outside Europe. Sandoz's filing asks the European Commission to review the trade practices and consider remedial action under anti-dumping rules.
Observers will watch how the European Commission responds to the draft complaint and whether it initiates an investigation that could lead to duties or other trade remedies. Sandoz framed the action as necessary to protect both public-health related supply chains and economic security tied to pharmaceutical manufacturing.
Summary
Sandoz has lodged a draft anti-dumping complaint at the European Commission concerning Chinese imports of amoxicillin. The company claims Chinese producers are engaging in below-cost pricing and benefiting from state subsidies, contributing to a concentration of antibiotic active ingredient production outside Europe and jeopardizing the continent's remaining vertically integrated penicillin capacity.
Key points
- Sandoz filed a draft anti-dumping complaint with the European Commission on Thursday focused on Chinese amoxicillin imports.
- The company says it runs the only major vertically integrated penicillin production network left in Europe and warns of a risk to domestic antibiotic manufacturing capacity.
- Sectors affected include pharmaceuticals, healthcare supply chains and trade-exposed manufacturing.
Risks and uncertainties
- Potential regulatory outcomes - it is uncertain whether the European Commission will open a formal investigation or impose trade remedies, which could alter market dynamics for antibiotic ingredients.
- Supply concentration - with up to 90% of global antibiotic active ingredients produced outside Europe, reliance on non-European sources poses supply resilience risks for the pharmaceutical sector and public health provisioning.
- Market-distorting practices - claims of below-cost pricing and state subsidies create uncertainty for European producers, affecting margins and investment decisions in the specialty pharmaceutical manufacturing sector.